- Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount.
- The companies’ new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug’s monthly cost from a list price of around $606 to $346.
- But the discounted price of Eliquis is still more than nine times the average monthly out-of-pocket cost paid by patients who are commercially insured, and significantly higher than Medicare’s new negotiated price for the drug under the Inflation Reduction Act.
Bristol Myers Squibb
and
Pfizer
on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount.
Stream San Diego News for free, 24/7, wherever you are with NBC 7.
The move comes as the Trump administration ramps up pressure on the pharmaceutical industry to
cut drug prices
, and threatens to
impose sweeping tariffs
on pharmaceuticals imported into the U.S.
The companies’ new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug’s monthly cost from a list price of around $606 to $346. Starting Sept. 8, uninsured, underinsured and self-pay patients will be able to purchase the medicine directly from the Eliquis 360 Support program, which will ship their prescriptions directly to their homes.
Get top local San Diego stories delivered to you every morning with our News Headlines newsletter.
But the discounted price of Eliquis is still
more than nine times the average monthly out-of-pocket cost
of $38 paid by patients who are commercially insured. The price under the new program is also significantly higher than the $231 per month price that Medicare negotiated under a provision of the Biden administration’s Inflation Reduction Act. That negotiated price is set to take effect next year.
The negotiated price is what Medicare will pay for Eliquis, and does not set what Medicare patients will pay for the drug now or in the future, Bristol Myers Squibb and Pfizer said in a joint statement. They added that the negotiated price does not reflect “the substantial clinical and economic value of this essential medicine.”
More than 90% of Eliquis prescriptions in the U.S. are currently covered through insurance. But Bristol Myers Squibb and Pfizer said the new effort aims to expand access to the treatment, reduce out-of-pocket costs for patient and provide transparent pricing for a different group of patients.
Money Report
Defense manufacturing startup Hadrian closes $260 million funding round led by Peter Thiel’s Founders Fund
Amazon cuts some jobs in cloud computing unit as layoffs continue
“This program passes more savings directly to patients and demonstrates our continued focus on identifying innovative solutions that foster the best outcomes for each individual while prioritizing access to care,” said Bristol Myers Squibb CEO Chris Boerner.
In a note on Thursday, Leerink Partners analyst David Risinger said he believes the move came in response to Trump’s plan to lower U.S. drug costs by linking prices to those paid in other developed countries. The president
signed
an executive order on that plan in May.
Risinger said the drugmakers already offer hefty rebates on Eliquis to pharmacy benefit managers, so the firm does not expect the program to create a “net pricing headwind” for Bristol Myers Squibb and Pfizer.
Also on CNBC
-
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
-
Healthy Returns: Chinese obesity may become a rival to Eli Lilly’s Zepbound
-
Whoop says FDA is ‘overstepping’ with warning about blood pressure feature
